Monitoring and Dosing of Argatroban in a Patient With Antiphospholipid Syndrome. (December 2021)

• Record Type: Journal Article
• Authors: Dooling, Karli; Haan, Bradley
• Is Part Of: Hospital pharmacy. Volume 56:Number 6(2021)
• Page Start: 706
• Page End: 708
• Publication Date: 2021-12
• Subjects: anticoagulants -- blood -- disease management -- monitoring drug therapy; Hospital pharmacies -- Periodicals; Pharmacy Service, Hospital; Hospital pharmacies; Periodicals; Periodicals; 615.1
• DOI: 10.1177/0018578720946765
• Languages: English
• ISSNs: 0018-5787

Abstract

Background: This case reports outlines argatroban dosing and necessary dose adjustments in a 56 year-old male with a past medical history of antiphospholipid syndrome and heparin-induced thrombocytopenia.Method: Argatroban was initiated as a fixed dose of 0.5 µg/kg/min with all initial aPTTs above goal. Argatroban was held for a procedure and re-initiated at 0.25 µg/kg/min. The dose was increased or decreased by 25% from the current rate based on supratherapeutic and subtherapeutic aPTTs, respectively.Results: The patient remained on argatroban for 6 total days, while achieving goal aPTT levels with no VTE or bleeding events.Conclusion: Our patient represents the first reported case of monitoring argatroban with aPTTs in an individual with APS.